Radiofrequency Ablation Treatment for Liver Metastasis

RFA: A Ray of Hope for Liver Metastasis from Gastric Cancer?

Nico Varela in Health & Wellness July 2025 • 5 min read.

"Discover how Radiofrequency Ablation (RFA) offers new hope for treating liver metastasis originating from gastric cancer, potentially improving outcomes compared to traditional chemotherapy."

Gastric cancer remains a formidable global health challenge, ranking as the second most common cause of cancer-related deaths in Asia. The insidious nature of this disease often leads to metastasis, with the liver being a frequent site of secondary tumor development. In fact, recent data indicates that liver metastasis is the most common metastatic cancer in the north of Iran, underscoring the urgent need for effective treatment strategies.

Traditional approaches to managing liver metastasis from gastric cancer typically involve systemic chemotherapy, which aims to target cancer cells throughout the body. While chemotherapy can be effective in slowing disease progression, it often comes with significant side effects that can impact a patient's quality of life. Moreover, chemotherapy may not always be successful in eradicating liver tumors, particularly in cases where the lesions are resistant to treatment.

In light of these challenges, researchers have been exploring alternative treatment modalities for liver metastasis from gastric cancer. One promising approach is radiofrequency ablation (RFA), a minimally invasive technique that uses heat to destroy cancer cells. RFA has emerged as a potential alternative to traditional chemotherapy, offering the possibility of improved outcomes with fewer side effects. This article delves into a clinical trial investigating the efficacy of RFA in treating metastatic liver tumors originating from gastric cancer, shedding light on its potential as a valuable tool in the fight against this deadly disease.

RFA vs. Chemotherapy: Which Treatment Offers Better Outcomes for Liver Metastasis?

Radiofrequency Ablation Treatment for Liver Metastasis

A randomized clinical trial was conducted to evaluate the efficacy of radiofrequency ablation (RFA) in treating metastatic liver tumors originating from gastric cancer. The study enrolled 43 patients with metastatic lesions, ensuring that each lesion was less than 5 cm in size. These patients were then randomly assigned to two treatment groups: one receiving chemotherapy and RFA (group A), and the other receiving chemotherapy alone (group B). The primary endpoint was to assess changes in tumor size and contrast enhancement via MRI.

The study population consisted of 26 males and 17 females, with a mean age of 62.51 ± 12.12 years. There were no significant differences between the two groups in terms of age and gender, ensuring a fair comparison of treatment outcomes. The majority of patients (93.02%) had metastasis involving the right hepatic lobe, highlighting a common pattern in liver metastasis. The mean size of metastases was similar in both groups, measuring 2.96 ± 1.14 cm in group A and 3.01 ± 0.96 cm in group B.

Complete Lesion Clearance: The results revealed a significant difference in treatment outcomes between the two groups. In group A (chemotherapy and RFA), 14 out of 21 patients (66.6%) achieved complete lesion clearance, indicating successful eradication of liver tumors.
Chemotherapy Alone Ineffective: In stark contrast, none of the patients in group B (chemotherapy alone) experienced complete lesion clearance, underscoring the limitations of chemotherapy as a standalone treatment for liver metastasis from gastric cancer.
Size Matters: Further analysis revealed that lesions smaller than 3 cm in size responded more favorably to RFA treatment, suggesting that RFA may be particularly effective for smaller liver tumors.

These findings suggest that RFA, when combined with chemotherapy, offers a significant advantage over chemotherapy alone in treating liver metastasis from gastric cancer. The ability to achieve complete lesion clearance in a substantial proportion of patients highlights the potential of RFA as a valuable treatment option, especially for smaller tumors. The study also underscores the need for personalized treatment strategies that take into account factors such as tumor size and location to optimize patient outcomes.

The Future of Liver Metastasis Treatment: RFA and Beyond

This study provides compelling evidence that RFA is a safe and effective treatment option for liver metastasis from gastric adenocarcinoma, especially when combined with chemotherapy. The therapeutic effect of chemotherapy in combination with RFA is more pronounced than systemic chemotherapy alone, particularly in lesions smaller than 3cm. As research continues to evolve, the integration of RFA into treatment protocols may offer hope for improved outcomes and enhanced quality of life for individuals battling this challenging condition.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is Radiofrequency Ablation (RFA), and how does it work in treating liver metastasis from gastric cancer?

Radiofrequency Ablation (RFA) is a minimally invasive technique that uses heat generated by radiofrequency energy to destroy cancer cells. In the context of liver metastasis from gastric cancer, RFA is used to target and eliminate tumors that have spread to the liver. A needle-like probe is inserted into the liver tumor, and radiofrequency waves are emitted, creating heat that destroys the cancerous tissue. This approach offers a localized treatment option, potentially improving outcomes and reducing side effects compared to systemic chemotherapy.

What were the key findings of the clinical trial comparing Radiofrequency Ablation (RFA) with chemotherapy for liver metastasis originating from gastric cancer?

The clinical trial compared the efficacy of RFA combined with chemotherapy versus chemotherapy alone in treating liver metastasis from gastric cancer. The primary outcome was the complete lesion clearance rate. The trial found that 66.6% of patients treated with RFA and chemotherapy achieved complete lesion clearance, meaning all liver tumors were successfully eradicated. In contrast, none of the patients treated with chemotherapy alone achieved complete lesion clearance. Furthermore, the study showed that RFA was particularly effective for smaller tumors, suggesting that tumor size plays a crucial role in treatment outcomes.

What are the potential advantages of using Radiofrequency Ablation (RFA) over traditional chemotherapy for liver metastasis from gastric cancer?

The main advantage of Radiofrequency Ablation (RFA) over chemotherapy is the potential for improved outcomes with fewer side effects. While chemotherapy is a systemic treatment that targets cancer cells throughout the body, it often comes with significant adverse effects, such as nausea, hair loss, and fatigue. RFA, on the other hand, is a localized treatment, meaning it directly targets the liver tumors without affecting the entire body to the same extent. The clinical trial's findings of a higher complete lesion clearance rate in patients treated with RFA combined with chemotherapy indicate that RFA can be more effective, especially for smaller lesions.

How does the size of the liver metastasis impact the effectiveness of Radiofrequency Ablation (RFA) as a treatment option?

The clinical trial revealed that the size of the liver metastases significantly impacts the effectiveness of Radiofrequency Ablation (RFA). The results showed that RFA was particularly effective in treating smaller tumors, specifically those less than 3 cm in size. This suggests that RFA may be most beneficial when used early in the course of the disease, when tumors are smaller. As tumors grow larger, the effectiveness of RFA may decrease, highlighting the importance of early detection and treatment. This also underscores the need for personalized treatment strategies, considering factors like tumor size to optimize patient outcomes.

What does the future hold for the treatment of liver metastasis from gastric cancer, considering the role of Radiofrequency Ablation (RFA)?

The future of treating liver metastasis from gastric cancer looks promising, with Radiofrequency Ablation (RFA) playing a significant role. The clinical trial's results suggest that RFA, especially when combined with chemotherapy, can be a valuable tool. This integration into treatment protocols may offer hope for improved patient outcomes and enhanced quality of life. The focus is on incorporating RFA as part of a comprehensive treatment strategy that considers factors like tumor size. As research continues, there may be further advancements in RFA technology and its application, leading to even better results in combating this challenging disease. The potential for personalized treatment plans, including RFA, can tailor therapies to each patient's specific situation.